A product discussed on No Priors: AI, Machine Learning, Tech, & Startups.

Powering AI-Driven Drug Discovery with President of Isomorphic Labs Max Jaderberg
Nov 12, 2026 · 39:16
Isomorphic Labs president Max Jaderberg tells Elad Gil that drug discovery must move from empirical trial and error onto computers, using predictive AI models that reach experimental accuracy. AlphaFold was the first proof deep learning could generalize in biology, prompting Isomorphic's 2021 founding. He blames the empirical process for drugs costing $1.5 billion over 15 years with flat approvals, and clinic failures after rat toxicity tests prove only ~30% predictive. Isomorphic generates proprietary data, builds its drug design engine in-house, and focuses on oncology and immunology while partnering with pharma. He argues precise molecule engineering unlocks multidrug cocktails modulating whole pathways and expects predictive disease biology to step-change within five years.

The Changing Physics of Cybersecurity and Drug Development with OpenAI President Greg Brockman
Oct 15, 2026 · 39:23
OpenAI president Greg Brockman joins Sarah Guo and Elad Gil to argue AI now generates genuinely new knowledge, citing nearly 400 century-old math problems solved and claiming the same capability can crack the language of biology. He says results transfer only where data exists, flagging regulatory filings and wet-lab data as bottlenecks. He describes Dots, a proactive always-on agent tracking his inbox and calendar, and argues the best UI is no UI as AI generates interfaces on the fly. On cybersecurity, he says defenders have a window to apply peak intelligence, citing OpenAI pulling 25% of production engineers and a billion-dollar defender commitment, and argues security spend should vastly outstrip software spend. He closes that humans stay firmly in the driver's seat as models surpass them.
Powered by PodHood